Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUPELO: REC-4881 in Familial Adenomatous Polyposis (FAP)
NCT05552755Phase 2Recruiting
- Sponsor
- Recursion Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TAK-733 in familial adenomatous polyposis (FAP) (5 arms), sponsored by Recursion Pharmaceuticals. Primary endpoints: Maximum Plasma Drug Concentration, Time to Reach Cmax and 6 more. Started Jul 2023; status: recruiting.
02
Drugs
TAK-733
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT05552755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552755.